Trials / Completed
CompletedNCT00040521
Study Evaluating rhIL-11 in Active Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index \[CDAI\] score from 220-400).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Interleukin-11 (rhIL-11) |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2002-06-28
- Last updated
- 2013-02-08
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00040521. Inclusion in this directory is not an endorsement.